Work

Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.6_suppl.121

Authors: Scott T. Tagawa, Naveed Hassan Akhtar, Joseph Osborne, Paul J. Christos, Shankar Vallabhajosula, Stanley J. Goldsmith, Renee Kahn, Caryn Ecker, Himisha Beltran, Michael J. Morris, Matthew I. Milowsky, Neil Harrison Bander, David M. Nanus

Institutions: Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589687989

Cites:

Cited by: 3

Related to: 10